Example: Heart Attack

Clinical Trials Sponsored by Horizon Pharma, Inc

Total 27 results

NCT00986895

Completed

A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group

Conditions: Hepatic Encephalopathy; Urea Cycle Disorders
NCT00977600

Completed

A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)

Conditions: Healthy
NCT04040894

Approved for marketing

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

Conditions: Thyroid Eye Disease; Graves' Orbitopathy
NCT03461211

Active, not recruiting

Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study

Conditions: Thyroid Eye Disease
NCT03298867

Active, not recruiting

Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study

Conditions: Thyroid Eye Disease; Graves' Orbitopathy
NCT02473445

Terminated

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Conditions: Mitochondrial Diseases
NCT02023866

Completed

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease

Conditions: Inherited Mitochondrial Disease, Including Leigh Syndrome
NCT01868997

Completed

Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

Conditions: Thyroid Associated Ophthalmopathies; Thyroid-Associated Ophthalmopathy
NCT01744782

Completed

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

Conditions: Cystinosis
NCT01733316

Completed

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Conditions: Cystinosis
NCT01270347

Completed

Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients

Conditions: Cystic Fibrosis
NCT01197378

Completed

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Conditions: Cystinosis
NCT01180634

Completed

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Conditions: Cystic Fibrosis
NCT01000961

Completed

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Conditions: Cystinosis
NCT00872729

Completed

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Conditions: Cystinosis
NCT00840333

Completed

"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"

Conditions: Cystic Fibrosis
NCT00752414

Completed

A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Conditions: Chronic Obstructive Pulmonary Disease
NCT00739648

Completed

A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients

Conditions: Chronic Obstructive Pulmonary Disease
NCT00677365

Completed

Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients

Conditions: Cystic Fibrosis (CF)
NCT00661141

Completed

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

Conditions: Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
NCT00503490

Completed

Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis

Conditions: Cystic Fibrosis
NCT04125459

Recruiting

Assessing the Role of the NLRP3 Inflammasome in Intercritical Gout

Conditions: Gout
NCT04628338

Not yet recruiting

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

Conditions: Myelodysplastic Syndromes; Myeloid Leukemia; Allogeneic Stem Cell Transplantation
NCT02927158

Recruiting

Exome and Genome Analysis to Elucidate Genetic Etiologies and Population Characteristics in the Plain Community

Conditions: Undiagnosed Disease
NCT04583735

Not yet recruiting

A Study Evaluating TEPEZZA® Treatment in Patients With Chronic (Inactive) Thyroid Eye Disease

Conditions: Thyroid Eye Disease; Chronic (Inactive) Thyroid Eye Disease